Health ❯ Healthcare ❯ Pharmaceuticals

Drug Efficacy

Clinical Research Weight Loss Medications Patient Outcomes Tirzepatide GLP-1 Drugs Survival Rates Comparative Effectiveness Clinical Outcomes Oral Medications Lorundrostat Wegovy vs Zepbound Retatrutide Brepocitinib Dissolution Specifications Ubrogepant Studies Alzheimer's Medications Endocrine Therapy Clinical Trials Axitinib Properties Injectable Medications FDA Regulations Statistical Significance Zepbound and Wegovy Factor XIa Inhibitors Aspirin COVID-19 Combination Therapy Combination Therapies Resistance Mutations Adverse Effects Cholesterol Management GLP-1 Agonists Weight Loss Treatments Zanubrutinib UZEDY® vs Invega Sustenna® Lecanemab Donanemab Wegovy Deucrictibant GLP-1 Analogues Oral Phenylephrine Comparative Studies Semaglutide Side Effects Monoclonal Antibodies Leqembi Clinical Study Results Semaglutide Efficacy GLP-1 Therapies Clinical Benefit Kisqali (ribociclib) Weight Loss Results Patient Safety Preclinical Studies

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Officials say Yellow Card reports do not prove drugs caused harm.

EMA Committee Recommends Revoking Tavneos Authorization

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

Ocular Therapeutix Plans Q4 Filing for AXPAXLI After Reported FDA Alignment

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Priovant’s Brepocitinib Posts Strong Phase 2 Win in Cutaneous Sarcoidosis

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Amgen Reports Year-Long Weight-Loss Maintenance With Monthly or Quarterly MariTide Dosing

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

Bristol Myers and J&J Halt Milvexian Heart-Attack Trial After Futility Finding

Ascend Recalls 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Kisqali Cuts Recurrence in 5-Year NATALEE Results for High-Risk Early HR+/HER2- Breast Cancer

Teva’s Olanzapine LAI Shows No PDSS in Phase 3 SOLARIS Long-Term Data Presented at Psych Congress

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

Cidara’s CD388 Antiviral Achieves Up to 76% Flu Protection in Phase 2b Trial